[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pyrophosphate-fetuin-a-il1-il6-tnfalpha-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pyrophosphate-fetuin-a-il1-il6-tnfalpha-control":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100539203","inorganic-pyrophosphate-homeostasis-ppi-in-pediatric-chronic-kidney-disease-100539203",false,"NCT06300788","Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease","Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA","PPi-DIA","Inclusion Criteria:\n\nAll groups :\n\n* Minor patients (\\\u003C18 years)\n* Patients of both sexes\n* Informed patients and parents who have signed the informed consent form\n* Patients affiliated to social security\n\nControl group :\n\n\\- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up\n\nCKD groups :\n\n* Patients on dialysis for more than 3 months, regardless of technique\n* Kidney transplant patients\n* Patients with CKD, whatever the cause\n\nExclusion Criteria:\n\n* Progressive cancer or kidney disease\n* Treatments that may modify PPi concentration (e.g. bisphosphonates)","ALL","0 Years","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.",[28],"Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control",[30],"Pyrophosphate","RECRUITING","2026-07-24",{"date":34,"type":35},"2026-07-27","ACTUAL",{"date":37,"type":35},"2024-05-27",{"date":39,"type":22},"2027-11-27",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nice","OTHER"]